Skip to content

Study · Systematic review · n = 3,136 · 2024

7 results

Semaglutide and blood pressure: an individual patient data meta-analysis.

Kennedy C, Hayes P, Cicero AFG, Dobner S, Le Roux CW, McEvoy JW, Zgaga L, Hennessy M

European heart journal1 Oct 2024Cited by 45 (Europe PMC)

PMID39217502 (opens in a new tab)PMCIDPMC11458150 (opens in a new tab)DOI10.1093/eurheartj/ehae564 (opens in a new tab)PepBankPUB-39217502
Read at sourcePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults in three semaglutide 2.4 mg trials, systolic blood pressure fell more with semaglutide than with placebo overall.

    In plain wordsIn adults in three trials, systolic blood pressure fell more on semaglutide than on placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseChange in systolic blood pressure, all participants
    Study

    n = 3,136

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    2.4 mg · 68 weeksAs given in this study (human).

    Measurements

    Difference in SBP change
    −4.95 mmHg
    semaglutide vs placebo, overall

    Source sentences

    Summary
    The difference in SBP change between the treatment (n = 2109) and placebo (n = 1027) groups was -4.95 mmHg [95% confidence interval (CI) -5.86 to -4.05] overall.
    2 context sentences
    Summary · context
    Individual patient data (IPD) from three RCTs examining the effect of semaglutide 2.4 mg on body weight over 68 weeks were included.
    Summary · context
    Overall, 3136 participants were included.
  2. 02HumanSystematic reviewEfficacy outcome

    In participants with hypertension, systolic blood pressure fell more with semaglutide 2.4 mg than with placebo.

    In plain wordsIn people with high blood pressure, systolic blood pressure fell more on semaglutide than on placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseChange in systolic blood pressure, hypertension group (HTN)
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    2.4 mg · 68 weeksAs given in this study (human).

    Measurements

    Difference in SBP change
    −4.78 mmHg
    HTN

    Source sentences

    Summary
    This difference was -4.78 mmHg (95% CI -5.97 to -3.59) for HTN, -4.93 mmHg (95% CI -6.75 to -3.11) for HTN130, -4.09 mmHg (95% CI -7.12 to -1.06) for HTN140, and -3.16 mmHg (95% CI -8.69-2.37) for RH.
    2 context sentences
    Summary · context
    Individual patient data (IPD) from three RCTs examining the effect of semaglutide 2.4 mg on body weight over 68 weeks were included.
    Summary · context
    Overall, 3136 participants were included.
  3. 03HumanSystematic reviewEfficacy outcome

    In participants with baseline systolic blood pressure above 130 mmHg, systolic blood pressure fell more with semaglutide 2.4 mg than with placebo.

    In plain wordsIn people with a baseline systolic pressure above 130 mmHg, blood pressure fell more on semaglutide than on placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseChange in systolic blood pressure, baseline SBP above 130 mmHg
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    2.4 mg · 68 weeksAs given in this study (human).

    Measurements

    Difference in SBP change
    −4.93 mmHg
    HTN130

    Source sentences

    Summary
    This difference was -4.78 mmHg (95% CI -5.97 to -3.59) for HTN, -4.93 mmHg (95% CI -6.75 to -3.11) for HTN130, -4.09 mmHg (95% CI -7.12 to -1.06) for HTN140, and -3.16 mmHg (95% CI -8.69-2.37) for RH.
    2 context sentences
    Summary · context
    Individual patient data (IPD) from three RCTs examining the effect of semaglutide 2.4 mg on body weight over 68 weeks were included.
    Summary · context
    Overall, 3136 participants were included.
  4. 04HumanSystematic reviewEfficacy outcome

    In participants with baseline systolic blood pressure above 140 mmHg, systolic blood pressure fell more with semaglutide 2.4 mg than with placebo.

    In plain wordsIn people with a baseline systolic pressure above 140 mmHg, blood pressure fell more on semaglutide than on placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseChange in systolic blood pressure, baseline SBP above 140 mmHg
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    2.4 mg · 68 weeksAs given in this study (human).

    Measurements

    Difference in SBP change
    −4.09 mmHg
    HTN140

    Source sentences

    Summary
    This difference was -4.78 mmHg (95% CI -5.97 to -3.59) for HTN, -4.93 mmHg (95% CI -6.75 to -3.11) for HTN130, -4.09 mmHg (95% CI -7.12 to -1.06) for HTN140, and -3.16 mmHg (95% CI -8.69-2.37) for RH.
    2 context sentences
    Summary · context
    Individual patient data (IPD) from three RCTs examining the effect of semaglutide 2.4 mg on body weight over 68 weeks were included.
    Summary · context
    Overall, 3136 participants were included.
  5. 05HumanSystematic reviewEfficacy outcome

    In participants with apparent resistant hypertension, the systolic blood pressure difference between semaglutide 2.4 mg and placebo was not significant.

    In plain wordsIn people with hard-to-treat high blood pressure, the blood pressure change on semaglutide was not clearly different from placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeChange in systolic blood pressure, apparent resistant hypertension
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    2.4 mg · 68 weeksAs given in this study (human).

    Measurements

    Difference in SBP change
    −3.16 mmHg
    RH

    Source sentences

    Summary
    This difference was -4.78 mmHg (95% CI -5.97 to -3.59) for HTN, -4.93 mmHg (95% CI -6.75 to -3.11) for HTN130, -4.09 mmHg (95% CI -7.12 to -1.06) for HTN140, and -3.16 mmHg (95% CI -8.69-2.37) for RH.
    2 context sentences
    Summary · context
    Individual patient data (IPD) from three RCTs examining the effect of semaglutide 2.4 mg on body weight over 68 weeks were included.
    Summary · context
    Overall, 3136 participants were included.
  6. 06HumanSystematic reviewMechanism

    In adults in three semaglutide 2.4 mg trials, weight loss substantially mediated the reduction in systolic blood pressure.

    In plain wordsIn adults in three trials, much of the blood pressure drop on semaglutide came from weight loss.

    Peptide
    Semaglutide
    Outcome
    Not applicableMediation of systolic blood pressure reduction by weight loss
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    2.4 mg · 68 weeksAs given in this study (human).

    Source sentences

    Summary
    Reduction in SBP was mediated substantially by weight loss.
    2 context sentences
    Summary · context
    Individual patient data (IPD) from three RCTs examining the effect of semaglutide 2.4 mg on body weight over 68 weeks were included.
    Summary · context
    Overall, 3136 participants were included.
  7. 07HumanSystematic reviewEfficacy outcome

    In adults in three semaglutide 2.4 mg trials, the anti-hypertensive treatment intensity score decreased with semaglutide compared with placebo.

    In plain wordsIn adults in three trials, people on semaglutide needed less blood pressure medicine than people on placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseAnti-hypertensive treatment intensity score
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    2.4 mg · 68 weeksAs given in this study (human).

    Measurements

    Treatment intensity score difference
    −0.51
    semaglutide vs placebo

    Source sentences

    Summary
    The anti-hypertensive treatment intensity score decreased for those on semaglutide compared to placebo (-0.51; 95% CI -0.71 to -0.32).
    2 context sentences
    Summary · context
    Individual patient data (IPD) from three RCTs examining the effect of semaglutide 2.4 mg on body weight over 68 weeks were included.
    Summary · context
    Overall, 3136 participants were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.